

JW2286, a novel inhibitor directly targeting of STAT3, drug discovery for solid cancer including triple negative cancer



ONCOLOGY	Non-Clinical
Product Type	Small molecule
Indication	Metastatic Triple Negative Breast Cancer (mTNBC) Solid cancer with over-expressed or activated STAT3
Target	STAT3
MoA(Mechanism of Action)	JW2286 is a novel class of STAT3 inhibitor (allosteric N-terminal blocker) that simultaneously inhibits STAT3-mediated transcription and mitochondrial function to prevent cancer cell growth and metastasis by inducing apoptosis
Competitiveness	1) Novel mechanism of action - Allosteric inhibitor directly bound to the STAT3-N terminal domain 2) Precision medicine strategy - Predictive biomarker-driven preclinical efficacy data 3) Better efficacy and safety over clinical competitors (BBI-608, OPB-111077 etc)
Development Stage	Non-Clinical
Route of Administration	Oral medication (PO)